BioSpace News Archive

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.60 per share, for gross proceeds of $40.0 million to Optinose, before deducting underwriting discounts and before offering expenses.

Live moderated video webcast discussion among members of management on Thursday, November 18th at 9:00 AM ET

AIVITA Biomedical, Inc. today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress. The Singapore -based congress is being held virtually November 17-18 .

Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced the results of a clinical study that proved Cardiologs’ deep learning AI outperforms the Apple Watch ECG algorithm in the detection of atrial arrhythmias (AA), which are related to stroke risks.

PTC Therapeutics, Inc. announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET.

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced that it will be presenting positive results from a Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer in situ at the 2021 TIDES Europe event.

Boehringer Ingelheim announced today that Carine Boustany , Ph.D., Global Head, Development Science + Head, Development Site U.S., has been appointed to the BIO Board of Directors.

INOVIO (NASDAQ: INO), today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial (NCT04906629).

Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity.

Cedilla Therapeutics today announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance.